Connie C.W. Hsia

Prof. Connie C.W. Hsia

Internal Medicine Department, University of Texas Southwestern Medical Center, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Open access
HKHrishikesh S. Kulkarni
Hrishikesh S. Kulkarni
JLJanet S. Lee
Janet S. Lee
JBJulie A. Bastarache
Julie A. Bastarache
WKWolfgang Kuebler
Wolfgang Kuebler
GDGregory P. Downey
Gregory P. Downey
GMGutavo Matute-Bello
Gutavo Matute-Bello
Advancements in methods, technology, and our understanding of the pathobiology of lung injury have created the need to update the definition of experimental acute lung injury (ALI). We queried 50 participants with expertise in ALI and acute respiratory distress syndrome using a Delphi method composed of a series of electronic surveys and a virtual workshop. We propose that ALI presents as a “multidimensional entity” characterized by four “domains” that reflect the key pathophysiologic features and underlying biology of human acute respiratory distress syndrome. These domains are 1) histological evidence of tissue injury, 2) alteration of the alveolar–capillary barrier, 3) presence of an inflammatory response, and 4) physiologic dysfunction. For each domain, we present “relevant measurements,” defined as those proposed by at least 30% of respondents. We propose that experimental ALI encompasses a continuum of models ranging from those focusing on gaining specific mechanistic insights to those primarily concerned with preclinical testing of novel therapeutics or interventions. We suggest that mechanistic studies may justifiably focus on a single domain of lung injury, but models must document alterations of at least three of the four domains to qualify as “experimental ALI.” Finally, we propose that a time criterion defining “acute” in ALI remains relevant, but the actual time may vary based on the specific model and the aspect of injury being modeled. The continuum concept of ALI increases the flexibility and applicability of the definition to multiple models while increasing the likelihood of translating preclinical findings to critically ill patients.

1 April 2013
Verified
Book Chapter
Closed access
PDF file
Connie C.W. HsiaConnie C.W. Hsia
Connie C.W. Hsia
ASAnke Schmitz
Anke Schmitz
MLMarkus Lambertz
Markus Lambertz
SPSteven F. Perry
Steven F. Perry
JMJohn N. Maina
John N. Maina

15 March 2016
Verified
Book Chapter
Closed access
PDF file
Connie C.W. HsiaConnie C.W. Hsia
Connie C.W. Hsia
DHDallas M. Hyde
Dallas M. Hyde
EWEwald R. Weibel
Ewald R. Weibel

1 June 2014 in Acta Biomaterialia
Verified
Journal Article
Closed access
Jyothi MenonJyothi Menon
Jyothi Menon
PRPriya Ravikumar
Priya Ravikumar
APAmruta Pise
Amruta Pise
DGDipendra Gyawali
Dipendra Gyawali
Connie C.W. HsiaConnie C.W. Hsia
Connie C.W. Hsia
Kytai T. NguyenKytai T. Nguyen
Kytai T. Nguyen

1 August 2008 in Diabetes Care
Verified
Journal Article
Open access
WCWilliam W. Chance
William W. Chance
CRChanhaeng Rhee
Chanhaeng Rhee
CYCuneyt Yilmaz
Cuneyt Yilmaz
DDD. Merrill Dane
D. Merrill Dane
MPM. Lourdes Pruneda
M. Lourdes Pruneda
Connie C.W. HsiaConnie C.W. Hsia
Connie C.W. Hsia
OBJECTIVE—Alveolar microvascular function is moderately impaired in type 1 diabetes, as manifested by restriction of lung volume and diffusing capacity (DLCO). We examined whether similar impairment develops in type 2 diabetes and defined the physiologic sources of impairment as well as the relationships to glycemia and systemic microangiopathy. RESEARCH DESIGN AND METHODS—A cross-sectional study was conducted at a university-affiliated diabetes treatment center and outpatient diabetes clinic, involving 69 nonsmoking type 2 diabetic patients without overt cardiopulmonary disease. Lung volume, pulmonary blood flow (Q̇), DLCO, membrane diffusing capacity (measured from nitric oxide uptake [DLNO]), and pulmonary capillary blood volume (VC) were determined at rest and exercise for comparison with those in 45 healthy nonsmokers as well as with normal reference values. RESULTS—In type 2 diabetic patients, peak levels of oxygen uptake, Q̇ and DLCO, DLNO, and VC at exercise were 10–25% lower compared with those in control subjects. In nonobese patients (BMI 30 kg/m2). The slope of the increase in VC with respect to Q̇ was reduced ∼20% in patients regardless of BMI, consistent with impaired alveolar-capillary recruitment. Functional impairment was directly related to A1C level, retinopathy, neuropathy, and microalbuminuria in a sex-specific manner. CONCLUSIONS—Alveolar microvascular reserves are reduced in type 2 diabetes, reflecting restriction of lung volume, alveolar perfusion, and capillary recruitment. This reduction correlates with glycemic control and extrapulmonary microangiopathy and is aggravated by obesity.

2 November 2015 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
RIRoshni Iyer
Roshni Iyer
Connie C.W. HsiaConnie C.W. Hsia
Connie C.W. Hsia
Kytai T. NguyenKytai T. Nguyen
Kytai T. Nguyen
Inhalation of aerosolized compounds is a popular, non-invasive route for the targeted delivery of therapeutic molecules to the lung. Various types of nanoparticles have been used as carriers to facilitate drug uptake and intracellular action in order to treat lung diseases and/or to facilitate lung repair and growth. These include polymeric nanoparticles, liposomes, and dendrimers, among many others. In addition, nanoparticles are sometimes used in combination with small molecules, cytokines, growth factors, and/or pluripotent stem cells. Here we review the rationale and state-of-the-art nanotechnology for pulmonary drug delivery, with particular attention to new technological developments and approaches as well as the challenges associated with them, the emerging advances, and opportunities for future development in this field.